• Federal Court Invalidates Selection Patent For Lack Of Sound Prediction [PLAVIX® (Clopidogrel)]
  • January 16, 2012
  • Law Firm: Norton Rose Canada LLP - Montreal Office
  • On December 6, 2011, the Federal Court (per Boivin J.) held in a 247-page decision that sanofi-aventis’ patent for clopidogrel bisulfate (PLAVIX®) is invalid because the inventors failed to disclose the factual basis and line of reasoning for their sound prediction of utility in the specification.